DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
The new site enables end-to-end production of viral vector gene therapies
The new site enables end-to-end production of viral vector gene therapies
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Subscribe To Our Newsletter & Stay Updated